| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1016519716 |
| P356 | DOI | 10.1007/S11883-007-0012-9 |
| P3181 | OpenCitations bibliographic resource ID | 4235280 |
| P698 | PubMed publication ID | 17877925 |
| P50 | author | Lewis Kuller | Q88077314 |
| P2860 | cites work | Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families | Q27860677 |
| MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial | Q28214393 | ||
| Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease | Q28216782 | ||
| Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation | Q28613091 | ||
| Alzheimer's disease | Q29616743 | ||
| Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial | Q29617817 | ||
| Determinants of vascular dementia in the Cardiovascular Health Cognition Study. | Q30989421 | ||
| Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond | Q33702396 | ||
| Role of the low-density lipoprotein receptor-related protein in beta-amyloid metabolism and Alzheimer disease | Q33920923 | ||
| Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. | Q33921362 | ||
| Lipoproteins in the central nervous system | Q33922696 | ||
| Incidence of Alzheimer's disease in a rural community in India: the Indo-US study | Q33954880 | ||
| Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants | Q34164504 | ||
| Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. | Q34417321 | ||
| Poststroke dementia. | Q34461454 | ||
| Statins and the risk of dementia | Q34511970 | ||
| The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes | Q34847106 | ||
| Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease | Q35485586 | ||
| International studies in dementia with particular emphasis on populations of African origin | Q35538341 | ||
| Cholesterol, statins and dementia. | Q35940754 | ||
| Cholesterol and apolipoprotein E in Alzheimer's disease | Q36103897 | ||
| Can statin therapy really reduce the risk of Alzheimer's disease and slow its progression? | Q36308740 | ||
| Cholesterol in Alzheimer's disease | Q36317585 | ||
| Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. | Q36438054 | ||
| Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease | Q36546512 | ||
| Interventions for heart disease and their effects on Alzheimer's disease | Q36582781 | ||
| From brain to bile. Evidence that conjugation and omega-hydroxylation are important for elimination of 24S-hydroxycholesterol (cerebrosterol) in humans | Q43681969 | ||
| Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain | Q43885523 | ||
| Serum lipoprotein levels, statin use, and cognitive function in older women | Q43915654 | ||
| Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide | Q44187794 | ||
| Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study | Q44201251 | ||
| Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers. | Q44300030 | ||
| APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. | Q44657566 | ||
| Statins and cognitive function in the elderly: the Cardiovascular Health Study | Q46794954 | ||
| Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol | Q48161830 | ||
| Caloric intake and the risk of Alzheimer disease | Q48520005 | ||
| Importance of a novel oxidative mechanism for elimination of brain cholesterol. Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with 18O2 techniques in vivo and in vitro. | Q48578997 | ||
| Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. | Q51926808 | ||
| Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. | Q51933375 | ||
| Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. | Q52937381 | ||
| Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. | Q53265427 | ||
| Statin Use and the Risk of Incident Dementia | Q57392350 | ||
| Formation of oxysterols from different pools of cholesterol as studied by stable isotope technique: cerebral origin of most circulating 24S-hydroxycholesterol in rats, but not in mice | Q59306993 | ||
| Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study | Q72319626 | ||
| Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients | Q73462725 | ||
| Statin therapy in the treatment of Alzheimer disease: what is the rationale? | Q81631120 | ||
| P433 | issue | 2 | |
| P921 | main subject | dementia | Q83030 |
| P304 | page(s) | 154-161 | |
| P577 | publication date | 2007-04-01 | |
| P1433 | published in | Current Atherosclerosis Reports | Q20821076 |
| P1476 | title | Statins and dementia | |
| P478 | volume | 9 |
| Q37165703 | Current and future therapy in Alzheimer's disease. |
| Q37827489 | Current perspectives on pharmacotherapy of Alzheimer's disease |
| Q35394390 | Dementia and Alzheimer's disease: a new direction.The 2010 Jay L. Foster Memorial Lecture |
| Q38628959 | Electronegative Low-Density Lipoprotein L5 Impairs Viability and NGF-Induced Neuronal Differentiation of PC12 Cells via LOX-1. |
| Q34572020 | Frontiers in the pathogenesis of Alzheimer's disease |
| Q38819005 | Highly electronegative low-density lipoprotein L5 evokes microglial activation and creates a neuroinflammatory stress via Toll-like receptor 4 signaling. |
| Q41995769 | Increased membrane cholesterol might render mature hippocampal neurons more susceptible to beta-amyloid-induced calpain activation and tau toxicity |
| Q35947072 | Markers of cholesterol metabolism in the brain show stronger associations with cerebrovascular disease than Alzheimer's disease. |
| Q37198579 | Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately? |
| Q36553735 | Risk of dementia and death in the long-term follow-up of the Pittsburgh Cardiovascular Health Study-Cognition Study |
| Q35843502 | Statins and brain integrity in older adults: secondary analysis of the Health ABC study |
| Q34078486 | The association of statin use and statin type and cognitive performance: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study |
| Q33770940 | Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial |
| Q37139026 | Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trial |
Search more.